Role of Biosimilars in the Oncology Ecosystem
While biosimilars and generics are not the same, biosimilars are very likely to adopt the same role in the market over the next decade; however, their safety, efficacy, and general role in the clinical setting remains unclear.
Category
  • Best Practices
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Implementing Clinical Trials in the Community Setting
Many community practices do not have the necessary resources and expertise to offer clinical trials to patients, which limits access in remote areas.
Category
  • Best Practices
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Multidisciplinary Management of Advanced Kidney Cancer
Clinicians will benefit from a discussion of various patient cases using high-level clinical evidence that take into account patient risk, surgical resectability, cancer stage, and the emerging data from approved therapies to individualize the treatment and maximize outcomes.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Chronic Lymphocytic Leukemia
The management of histologic transformation of CLL to aggressive lymphomas remains an unmet clinical need since the standard of care is not established. Treatment selection for patients with CLL without del(17p)/TP53 mutation should be individualized based patient’s age, performance status, comorbid conditions, as well as the agent’s toxicity profile. Oncologists and hematologists need to understand the unique challenges associated with the management of histologic transformation of CLL.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Trimodal Therapy Approaches for Localized Rectal Cancer
Trimodal therapy approaches for localized rectal cancer continue to evolve as new data helps define the approaches that will best improve outcomes while reducing adverse effects, as well as which patients will benefit from these treatment methods.  Clinicians would benefit from education on relevant clinical trial results and how they may be best applied to clinical practice.
Category
  • Rectal Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Rectal Cancer
The determination of an optimal treatment plan for patients with rectal cancer is a complex process that is reliant on balancing the potential risks and benefits of each treatment option based on an individual patient’s characteristics. Clinicians must be educated about on emerging approaches to personalized treatment for patients with rectal cancer so that the most appropriate treatment options can be offered to each patient.
Category
  • Rectal Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Locoregional Management of Early-Stage Breast Cancer
Locoregional management strategies have considerably evolved.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Debate - What is Optimal First-Line Therapy for Chronic Lymphocytic Leukemia: Chemoimmunotherapy or Small Molecule Inhibitor Therapy?
The treatment landscape of first-line therapy for chronic lymphocytic leukemia (CLL) has evolved significantly in recent years. Educating the clinicians about the recent clinical advances and the benefits/risks associated with the use of chemoimmunotherapy vs. targeted therapy can help them to make informed clinical decisions and develop an individualized treatment plan.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Talking to Patients about Cancer Treatment, Risk Factors, and Treatment Cessation during the COVID-19 Pandemic
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Cardiovascular Health and Risk Management in Cancer Survivors
As the population of cancer survivors continues to grow, it becomes increasingly important for clinicians providing survivorship care to be informed about the increased risk for cardiovascular disease in this population, particularly as related to specific cancer treatment exposures and cardiovas
Category
  • Survivorship
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation

Pages